Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • ASCO Journal Club • HR+ • Breast Cancer, Metastatic • Her2-negative breast cancer
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
Answer from: Medical Oncologist at Academic Institution
Dato-DXd significantly reduced the risk of progressive disease or death compared to chemotherapy in patients with metastatic or inoperable HR+ HER2- breast cancer per TROPION-Breast01. It also showed an improved objective response rate and consistent benefit in improving progression-free survival ac...
Sign in or Register to read more